IP Library Granted Patent US 8,592,185
Granted Patent B2
US 8,592,185 · App. 13/565,954 · Granted Nov 26, 2013

Methods for detection of methyl-CpG dinucleotides

Inventor: John J. Dunn (Bellport, NY)
Assignee: Brookhaven Science Associates, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,592,185
App. No.
13/565,954
Granted
Nov 26, 2013
Kind
B2
Abstract

The invention provides methods for enriching methyl-CpG sequences from a DNA sample. The method makes use of conversion of cytosine residues to uracil under conditions in which methyl-cytosine residues are preserved. Additional methods of the invention enable to preservation of the context of me-CpG dinucleotides. The invention also provides a recombinant, full length and substantially pure McrA protein (rMcrA) for binding and isolation of DNA fragments containing the sequence 5′-C Me CpGG-3′. Methods for making and using the rMcrA protein, and derivatives thereof are provided.

Claims (29)

1. A method for enriching methyl-CpG sequences from a DNA sample comprising:

a) providing a DNA sample;

b) fragmenting the DNA by endonuclease digestion, restriction enzyme digestion or mechanical methods to form a plurality of double stranded fragments having a convenient size range;

c) treating the plurality of double stranded fragments of b) under conditions suitable for conversion of all cytosine bases to uracil, which conditions are suitable for conservation of methylated cytosine bases, to form a plurality of cytosine-free double stranded DNA fragments;

d) amplifying the cytosine-free fragments, or subset thereof, to form an amplified fragment population in which all uracil bases are replaced with thymidine and all methyl-cytosine bases are replaced with cytosine;

e) methylating all cytosine bases in CpG dinucleotide sequences in the amplified fragment population of d); and

f) collecting all methylated amplified fragments from e), thereby enriching for methyl-CpG sequences from the DNA sample.

2. The method according to claim 1 in which the DNA is fragmented by restriction enzyme digestion.

3. The method according to claim 2 in which the restriction enzyme digestion is repeated to ensure complete digestion.

4. The method according to claim 1 in which the plurality of double stranded fragments have sticky ends.

5. The method according to claim 1 in which the plurality of double stranded fragments have blunt ends.

6. The method according to claim 1 in which the ends of the double stranded fragments are treated to produce blunt ends.

7. The method according to claim 1 in which a double stranded amplification cassette is ligated to both ends of the plurality of double stranded DNA fragments produced in b).

8. The method according to claim 1 in which the cytosine bases in the amplified fragment population are methylated using a methyl transferase that specifically methylates CpG dinucleotide sequences.

9. The method according to claim 8 in which the methylation is repeated to ensure complete methylation of all CpG dinucleotides sequences.

10. The method according to any one of claims 1 , 8 or 9 in which methylation is accomplished using CpG methyltransferase (M.SssI).

11. The method according to claim 1 in which the methylated amplified fragments from e) are collected using a Me-CpG binding ligand.

12. The method according to claim 11 in which the Me-CpG binding ligand is selected from the group consisting of a Me-CpG antibody, the methyl binding domain (MBD) of MeCP2, the methyl binding domain MBD2, the complex of MBD2 and MBD3L1, an antibody-like construct of methyl-CpG binding domain protein 2 (MBD2) and human-F c , and rMcrA protein or combinations thereof.

13. The method according to claim 12 in which the binding ligand is fused to an affinity tag.

14. The method according to claim 12 in which the binding ligand is MDB2 or the MBD2/MBD3L1 complex.

15. The method according to claim 12 in which the binding ligand is rMcrA protein.

16. The method according to claim 12 in which the collected methylated fragments are collected using the MBD2/MBD3L1 complex.

17. The method according to claim 16 in which the collected methylated fragments are contacted with a second methyl-CpG binding ligand which separates methylated fragments having the sequence C Me CpGG from fragments lacking the sequence.

18. The method according to claim 17 in which the second methyl-CpG binding ligand is rMcrA protein.

19. The method according to claim 1 in which the convenient size range is from about 100 to about 2000 base pairs.

20. The method according to claim 19 in which the convenient size range is from about 100 to about 1000 base pairs.

21. The method according to claim 20 in which the convenient size range is from about 100 to about 500 base pairs.

22. The method according to claim 21 in which the convenient size range is from about 100 to about 250 base pairs.

23. A method for enriching methyl-CpG sequences from a DNA sample comprising: fragmenting the DNA by restriction enzyme digestion to form a plurality of double stranded DNA fragments, treating the fragmented DNA under conditions suitable for conversion of all cytosine bases to uracil, which conditions are suitable for conservation of methylated cytosine bases, to form a plurality of double stranded cytosine-free DNA fragments; amplifying the cytosine-free DNA fragments, or subset thereof, to form a population of amplified DNA fragments in which all uracil bases are replaced with thymidine and all methyl-cytosine bases are replaced with cytosine; methylating all cytosine bases in CpG dinucleotide sequences in the amplified DNA fragments; and collecting the amplified DNA fragments having methylated CpG dinucleotides, thereby enriching for methyl-CpG sequences from the DNA sample.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 3, 2013
From: BROOKHAVEN SCIENCE ASSOCIATES, LLC
To: ENERGY, UNITED STATES DEPARTMENT OF
Reel/Frame 030583/0619 →
Continuity (3)
Division 12507522 · Jul 22, 2009
Provisional Application 61083242 · Jul 24, 2008
Related Publication 20130040343A1 · Feb 14, 2013